Compare BRZE & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRZE | ICUI |
|---|---|---|
| Founded | 2011 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.6B |
| IPO Year | 2021 | 1992 |
| Metric | BRZE | ICUI |
|---|---|---|
| Price | $21.60 | $149.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 5 |
| Target Price | $44.73 | ★ $179.50 |
| AVG Volume (30 Days) | ★ 2.5M | 235.7K |
| Earning Date | 12-09-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $693,412,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | $25.69 | N/A |
| Revenue Next Year | $17.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.95 | N/A |
| 52 Week Low | $21.41 | $107.00 |
| 52 Week High | $47.60 | $173.85 |
| Indicator | BRZE | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 25.19 | 48.87 |
| Support Level | $22.66 | $150.80 |
| Resistance Level | $26.17 | $160.29 |
| Average True Range (ATR) | 1.60 | 4.66 |
| MACD | -0.50 | -0.74 |
| Stochastic Oscillator | 2.12 | 19.41 |
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates majority of its revenue from the United States.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.